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The goal of the research study was to shed light on a
promising research area which may prove to be a safer
more specific vaccine candidate; PfRH5 on merozoites.
Erythrocyte invasion is paramount to the pathogenesis of
P. falciparum requiring a series of extracellular recogni-
tion between the erythrocyte receptors and merozoites
ligands. Of the known receptor-ligand interactions, one
has been found essential to erythrocyte invasion in all
P. falciparum strains; P. falciparum reticulocyte-binding
protein homologue, PfRh5. This ligand binds to erythro-
cytes via basigin, an Ok blood group antigen and a type I
integral membrane receptor consisting of many ligands.
Basigin, also known as CD147, is a protein receptor on
red blood cells, and a member of the immunoglobulin
superfamily (Crosnier et al. 2011). It has further been
found that a cysteine-rich protein called P. falciparum
Rh5 interacting protein, PfRipr, forms a complex with
PfRh5 on merozoites, where one study found antibodies
to PfRipr1 to effectively inhibit merozoites attachment
and invasion in erythrocytes (Chen et al. 2011).
The most effective targeting strategy seems to be pre-
venting PfRh5 on merozoites from binding the receptor
basigin on red blood cells (RBC). This receptor is essential
for Plasmodium falciparum to enter RBC by binding basi-
gin via PfRh5 protein on the malaria parasite. Basigin is a
member of the immunoglobulin superfamily, a group of
cell surface soluble proteins involved in the binding, adhe-
sion, and recognition processes of cells. Since PfRH5 is spe-
cific to merozoites, a vaccine based on PfRh5 would not
affect RBCs or other parts of the body, likely not initiating
an auto-immune response. This presents the best opportu-
nity due to the specificity of PfRH5 which makes it a “safe”
and effective vaccine targeting strategy.
Due to the specificity of the attack method used by
P. falciparum, it seems evident that the vaccine must
target a specific receptor of one of the parasites many
stages. The focus of the study is to shed light on this
newly found research and to create a vaccine in the
future that develops antibodies against the parasite ligand
of Basigin, Rh5, since PfRh5 protein on the parasite binds
to basigin. Due to the need of merozoites to enter and
replicate in RBC, this seems like the most plausible vaccine
development. Since humans are both the carriers and
“spreaders” to mosquitos, it is paramount to find a vaccine
for humans to stop the spread of gametocytes to mosqui-
tos which would prevent sporozoites formation and the
re-infection of other humans. The author believes that
developing antibodies against the parasite ligand for basi-
gin will prevent merozoites invasion into erythrocytes.
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